Under the agreement, ABL will be responsible for the production and characterization of a master virus seed stock, a reservoir of virus produced under strict cGMP conditions.
The master virus seed stock will be used to support Inviragen’s development of a vaccine against plague.
ABL will also develop purified vaccine material to be used in future toxicology studies.
ABL CEO Thomas VanCott said that their expertise in cGMP manufacturing of viral products will provide Inviragen with the support they need in their development of a plague vaccine candidate.